Status:
COMPLETED
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
19-55 years
Phase:
PHASE1
Brief Summary
The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference i...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a history of or presence of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome), or uncorrected hypokalemia or hypomagnesemia
- Has a history of clostridium difficile-associated diarrhea
Key Trial Info
Start Date :
July 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 8 2024
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06609161
Start Date
July 16 2024
End Date
August 8 2024
Last Update
September 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion (Site 0001)
Lincoln, Nebraska, United States, 68502